What is Neurocrine Biosciences Inc's earnings per share (EPS)?

Neurocrine Biosciences Inc (NBIX) reported diluted earnings per share of $4.67 for fiscal year 2025. This represents a 41.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neurocrine Biosciences Inc (NBIX) Financials

NBIX

Trailing 12 months to June 30, 2026

Revenue $3.4B +34.4% YoY

Net Income $705.5M +102.6% YoY

EPS (Diluted) $6.82 +101.8% YoY

Free Cash Flow $865.6M +63.7% YoY

Market Cap $14.3B as of Oct 1, 2026

Price / Sales 4.2x on $3.4B revenue, trailing 12 months to June 30, 2026

Price / Earnings 20.3x on $705.5M net income, trailing 12 months to June 30, 2026

Price / Book 3.9x on $3.7B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 1, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 31, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NBIX SEC filings page.

Neurocrine Biosciences Inc (NBIX) reported $3.4B in revenue over the twelve months to Jun 30, 2026, up 34.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NBIX FY2025 2026-08-30

Neurocrine’s cash-rich commercialization scales revenue while rising reinvestment leaves leverage contained and cash conversion strong.

Cash conversion is the key earnings-quality signal: FY2025 operating cash flow was $782.7M versus net income of $478.6M, so accounting profit understated cash produced during the year. Free cash flow was $748.7M against only $34M of capital expenditures, showing that cash generation is not being consumed by heavy physical reinvestment.

Operating leverage has become less direct: operating margin narrowed from 24.2% in FY2024 to 21.6% in FY2025 even as revenue expanded. The simultaneous rise in R&D and selling costs to $1.0B and $1.2B suggests the latest growth required materially greater commercial and development investment.

Balance-sheet capacity remains conservative: FY2025 liabilities were $1.4B versus $3.3B of equity, a structure financed more by equity than obligations. Debt-to-equity was 0.4x and current ratio 3.4x, reinforcing capacity to fund operations without heavy borrowing.

Financial Health Signals

Financial Health Score 80/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Neurocrine Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Neurocrine Biosciences Inc has an operating margin of 21.6%, meaning the company retains $22 of operating profit per $100 of revenue. This strong profitability earns a score of 81/100, reflecting efficient cost management and pricing power. This is down from 24.2% the prior year.

Growth

Neurocrine Biosciences Inc's revenue surged 21.4% year-over-year to $2.9B, reflecting rapid business expansion. This strong growth earns a score of 85/100.

Leverage

Neurocrine Biosciences Inc has a moderate D/E ratio of 0.42. This balance of debt and equity financing earns a leverage score of 63/100.

Liquidity

With a current ratio of 3.39, Neurocrine Biosciences Inc holds $3.39 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.

Cash Flow

Neurocrine Biosciences Inc converts 26.2% of revenue into free cash flow ($748.7M). This strong cash generation earns a score of 90/100.

Returns

Neurocrine Biosciences Inc earns a strong 14.7% return on equity (ROE), meaning it generates $15 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 76/100. This is up from 13.2% the prior year.

Altman Z-Score Safe

7.88

Neurocrine Biosciences Inc scores 7.88, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($14.3B) relative to total liabilities ($1.4B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Neurocrine Biosciences Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.64x

For every $1 of reported earnings, Neurocrine Biosciences Inc generates $1.64 in operating cash flow ($782.7M OCF vs $478.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$959.0M

YoY+39.5%

QoQ+17.7%

5Y CAGR+27.1%

Neurocrine Biosciences Inc generated $959.0M in revenue in Q2 2026. This represents an increase of 39.5% from the same quarter a year earlier. Against the prior quarter it is up 17.7%.

EBITDA

$176.3M

YoY+15.3%

QoQ-12.2%

5Y CAGR+21.9%

Neurocrine Biosciences Inc's EBITDA was $176.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.3% from the same quarter a year earlier. Against the prior quarter it is down 12.2%.

Net Income

$144.4M

YoY+34.3%

QoQ-27.0%

5Y CAGR+27.8%

Neurocrine Biosciences Inc reported $144.4M in net income in Q2 2026. This represents an increase of 34.3% from the same quarter a year earlier. Against the prior quarter it is down 27.0%.

EPS (Diluted)

$1.39

YoY+31.1%

QoQ-27.2%

5Y CAGR+26.4%

Neurocrine Biosciences Inc earned $1.39 per diluted share (EPS) in Q2 2026. This represents an increase of 31.1% from the same quarter a year earlier. Against the prior quarter it is down 27.2%.

Cash & Balance Sheet

Free Cash Flow

$128.6M

YoY+43.7%

QoQ-5.9%

5Y CAGR+5.4%

Neurocrine Biosciences Inc generated $128.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 43.7% from the same quarter a year earlier. Against the prior quarter it is down 5.9%.

Cash & Debt

$332.4M

YoY+25.9%

QoQ+24.7%

5Y CAGR-2.0%

10Y CAGR+14.4%

Neurocrine Biosciences Inc held $332.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

102M

YoY+2.5%

QoQ+1.1%

5Y CAGR+1.4%

10Y CAGR+1.6%

Neurocrine Biosciences Inc had 102M shares outstanding in Q2 2026. This represents an increase of 2.5% from the same quarter a year earlier. Against the prior quarter it is up 1.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

97.6%

YoY-0.8pp

QoQ-0.7pp

5Y change-1.3pp

Neurocrine Biosciences Inc's gross margin was 97.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.

Operating Margin

15.8%

YoY-5.4pp

QoQ-7.9pp

5Y change-5.9pp

Neurocrine Biosciences Inc's operating margin was 15.8% in Q2 2026, reflecting core business profitability. This is down 5.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.9 percentage points.

Net Margin

15.1%

YoY-0.6pp

QoQ-9.2pp

5Y change+0.4pp

Neurocrine Biosciences Inc's net profit margin was 15.1% in Q2 2026, showing the share of revenue converted to profit. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.2 percentage points.

Return on Equity

3.9%

YoY-0.1pp

QoQ-1.9pp

5Y change+0.6pp

10Y change+14.5pp

Neurocrine Biosciences Inc's ROE was 3.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.

Capital Allocation

R&D Spending

$326.7M

YoY+33.7%

QoQ+10.3%

5Y CAGR+34.3%

Neurocrine Biosciences Inc invested $326.7M in research and development in Q2 2026. This represents an increase of 33.7% from the same quarter a year earlier. Against the prior quarter it is up 10.3%.

Share Buybacks

$12.0M

YoY-32.2%

QoQ-77.8%

Neurocrine Biosciences Inc spent $12.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 32.2% from the same quarter a year earlier. Against the prior quarter it is down 77.8%.

Capital Expenditures

$7.8M

YoY-37.6%

QoQ-14.3%

5Y CAGR+12.6%

10Y CAGR+13.3%

Neurocrine Biosciences Inc invested $7.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 37.6% from the same quarter a year earlier. Against the prior quarter it is down 14.3%.

NBIX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBIX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.4B	$2.9B+21.4%	$2.4B+24.8%	$1.9B+26.8%	$1.5B+31.3%	$1.1B+8.4%	$1.0B+32.7%	$788.1M+74.7%	$451.2M+179.2%	$161.6M+977.5%	$15.0M-24.1%	$19.8M	$0-100.0%	$2.9M-94.5%	$53.1M-31.4%	$77.4M
Cost of Revenue	$68.6M	$52.1M+53.2%	$34.0M-14.4%	$39.7M+71.1%	$23.2M+62.2%	$14.3M+41.6%	$10.1M	N/A	$4.9M+289.9%	$1.3M	$0	$0	N/A	N/A	N/A	N/A
Gross Profit	$3.3B	$2.8B+21.0%	$2.3B+25.7%	$1.8B+26.1%	$1.5B+30.9%	$1.1B+8.1%	$1.0B	N/A	$446.3M+178.3%	$160.4M+969.1%	$15.0M-24.1%	$19.8M	N/A	N/A	N/A	N/A
R&D Expenses	$1.1B	$1.0B+38.9%	$731.1M+29.4%	$565.0M+21.8%	$463.8M+41.4%	$328.1M+19.3%	$275.0M	N/A	$160.5M+31.8%	$121.8M+29.2%	$94.3M+15.7%	$81.5M+75.5%	$46.4M+18.3%	$39.2M+5.6%	$37.2M+20.1%	$31.0M
SG&A Expenses	$1.4B	$1.2B+14.8%	$1.0B+13.5%	$887.6M+17.9%	$752.7M+29.0%	$583.3M+34.6%	$433.3M+22.4%	$354.1M+42.3%	$248.9M+46.5%	$169.9M+149.6%	$68.1M+109.6%	$32.5M+80.6%	$18.0M+34.7%	$13.3M-0.7%	$13.4M+7.9%	$12.5M
Operating Income	$794.8M	$619.1M+8.5%	$570.5M+127.4%	$250.9M+0.8%	$249.0M+142.9%	$102.5M-37.1%	$163.0M+125.4%	$72.3M+96.5%	$36.8M+128.0%	-$131.4M+10.9%	-$147.4M-56.4%	-$94.2M-46.3%	-$64.4M-29.7%	-$49.7M-3530.8%	$1.4M-95.7%	$33.9M
EBITDA	N/A	$649.2M+8.6%	$597.6M+119.5%	$272.2M+2.9%	$264.6M+133.3%	$113.4M-33.9%	$171.6M+115.3%	$79.7M+95.2%	$40.8M+131.7%	-$129.0M+11.6%	-$145.9M-56.6%	-$93.2M-46.6%	-$63.6M-29.7%	-$49.0M-2428.1%	$2.1M-93.9%	$34.6M
Interest Expense	N/A	N/A	N/A	$4.6M-35.2%	$7.1M-72.5%	$25.8M-21.3%	$32.8M+2.5%	$32.0M+4.9%	$30.5M+56.2%	$19.5M	$0	$0	N/A	N/A	N/A	N/A
Income Tax	$234.7M	$226.8M+56.7%	$144.7M+75.6%	$82.4M+38.7%	$59.4M+403.4%	$11.8M+103.9%	-$300.6M-3264.2%	$9.5M+1257.1%	$700K	$0	$0	$0	$0	$0	$0	$0
Net Income	$705.5M	$478.6M+40.2%	$341.3M+36.7%	$249.7M+61.6%	$154.5M+72.4%	$89.6M-78.0%	$407.3M+1000.8%	$37.0M+75.4%	$21.1M+114.8%	-$142.5M-1.0%	-$141.1M-58.7%	-$88.9M-46.9%	-$60.5M-31.4%	-$46.1M-1017.2%	$5.0M-86.6%	$37.6M
EPS (Basic)	N/A	$4.81+41.5%	$3.40+32.8%	$2.56+59.0%	$1.61+69.5%	$0.95-78.3%	$4.38+995.0%	$0.40+73.9%	$0.23+114.2%	-$1.62+0.6%	-$1.63-55.2%	-$1.05-29.6%	-$0.81-17.4%	-$0.69-962.5%	$0.08-88.2%	$0.68
EPS (Diluted)	$6.82	$4.67+41.9%	$3.29+33.2%	$2.47+58.3%	$1.56+69.6%	$0.92-77.9%	$4.16+966.7%	$0.39+77.3%	$0.22+113.6%	-$1.62+0.6%	-$1.63-55.2%	-$1.05-29.6%	-$0.81-17.4%	-$0.69-962.5%	$0.08-88.1%	$0.67
Diluted Shares (Avg)	N/A	103M-1.2%	104M+2.7%	101M+2.1%	99M+1.0%	98M+0.1%	98M+2.2%	96M+0.3%	95M+8.3%	88M+1.6%	87M+2.6%	84M+13.3%	75M+11.3%	67M+0.1%	67M+18.8%	56M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$959.0M+39.5%	$814.5M+42.2%	$805.5M+28.3%	$794.9M+27.8%	$687.5M+16.5%	$572.6M+11.1%	$627.7M+21.8%	$622.1M+24.7%
Cost of Revenue	$23.2M+105.3%	$13.8M+50.0%	$17.6M+89.2%	$14.0M+75.0%	$11.3M+22.8%	$9.2M+22.7%	$9.3M+9.4%	$8.0M-28.6%
Gross Profit	$935.8M+38.4%	$800.7M+42.1%	$787.9M+27.4%	$780.9M+27.2%	$676.2M+16.4%	$563.4M+10.9%	$618.4M+22.0%	$614.1M+25.9%
R&D Expenses	$326.7M+33.7%	$296.2M+12.5%	$258.2M+39.1%	$250.0M+28.2%	$244.3M+27.8%	$263.2M+65.1%	$185.6M+35.0%	$195.0M+37.1%
SG&A Expenses	$439.7M+53.6%	$318.5M+15.2%	$301.8M+4.9%	$291.6M+24.5%	$286.3M+18.3%	$276.5M+13.7%	$287.8M+31.5%	$234.3M+14.7%
Operating Income	$151.5M+4.1%	$193.4M+719.5%	$210.9M+48.5%	$239.0M+30.0%	$145.6M+0.1%	$23.6M-76.2%	$142.0M-5.5%	$183.8M+30.2%
EBITDA	$176.3M+15.3%	$200.7M+543.3%	$218.4M+46.5%	$246.7M+29.6%	$152.9M+0.1%	$31.2M-70.4%	$149.1M-4.4%	$190.3M+29.7%
Interest Expense	$2.9M	N/A	N/A	N/A	$0	N/A	N/A	N/A
Income Tax	$17.8M-65.8%	$48.9M+619.1%	$85.7M+44.0%	$82.3M+36.0%	$52.0M+54.8%	$6.8M+176.4%	$59.5M+17.8%	$60.5M+86.2%
Net Income	$144.4M+34.3%	$197.9M+2405.1%	$153.7M+49.1%	$209.5M+61.4%	$107.5M+65.4%	$7.9M-81.8%	$103.1M-30.2%	$129.8M+56.2%
EPS (Basic)	$1.43+31.2%	$1.97+2362.5%	$1.54+49.5%	$2.11+64.8%	$1.09+70.3%	$0.08-81.4%	$1.03-31.8%	$1.28+50.6%
EPS (Diluted)	$1.39+31.1%	$1.91+2287.5%	$1.48+48.0%	$2.04+64.5%	$1.06+68.3%	$0.08-81.0%	$1.00-31.5%	$1.24+51.2%
Diluted Shares (Avg)	104M+3.2%	103M+0.9%	N/A	103M-1.7%	101M-2.8%	103M-1.1%	N/A	104M+3.2%

NBIX Balance Sheet

NBIX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$4.6B+24.5%	$3.7B+14.4%	$3.3B+37.3%	$2.4B+14.3%	$2.1B+19.5%	$1.7B+32.8%	$1.3B+31.5%	$993.2M+21.5%	$817.6M+123.9%	$365.1M-23.1%	$474.8M+95.4%	$243.0M+57.1%	$154.7M-21.1%	$196.0M+41.6%	$138.4M
Current Assets	$2.5B+46.3%	$1.7B+7.3%	$1.6B+10.6%	$1.5B+49.4%	$972.8M-4.3%	$1.0B+22.3%	$831.0M+12.6%	$737.8M+33.0%	$554.9M+78.8%	$310.4M-19.2%	$384.1M+93.8%	$198.2M+33.5%	$148.5M-21.6%	$189.3M+42.9%	$132.5M
Cash & Equivalents	$713.0M+206.0%	$233.0M-7.2%	$251.1M-4.5%	$262.9M-22.9%	$340.8M+82.1%	$187.1M+66.6%	$112.3M-20.8%	$141.7M-44.4%	$254.7M+205.9%	$83.3M+12.2%	$74.2M+139.2%	$31.0M-30.8%	$44.8M-29.7%	$63.8M+27.2%	$50.1M
Short-Term Investments	$767.4M-9.0%	$843.1M+8.0%	$780.5M+7.4%	$726.4M+96.1%	$370.5M-39.6%	$613.9M+10.0%	$558.2M+9.6%	$509.2M+94.9%	$261.2M+16.6%	$224.1M-26.5%	$305.0M+87.3%	$162.8M+61.3%	$101.0M-7.6%	$109.3M+38.3%	$79.0M
Inventory	$69.0M+20.2%	$57.4M+49.9%	$38.3M+9.1%	$35.1M+15.1%	$30.5M+8.9%	$28.0M+61.8%	$17.3M+59.2%	$10.9M+960.9%	$1.0M	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$686.8M+43.4%	$479.1M+9.1%	$439.3M+25.5%	$350.0M+88.7%	$185.5M+18.1%	$157.1M+24.1%	$126.6M+120.5%	$57.4M+84.4%	$31.1M	$0	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$1.1B+43.7%	$739.5M+7.6%	$687.5M+129.6%	$299.4M-46.6%	$560.7M+146.9%	$227.1M-24.2%	$299.7M+38.7%	$216.0M-12.7%	$247.4M+468.8%	$43.5M-47.3%	$82.5M+120.0%	$37.5M	$0-100.0%	$480K	$0
Goodwill	$6.1M+7.0%	$5.7M-1.7%	$5.8M+7.4%	$5.4M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4B+22.1%	$1.1B+10.8%	$1.0B+54.2%	$660.9M-5.4%	$698.5M+14.8%	$608.5M-9.1%	$669.1M+30.6%	$512.4M+15.0%	$445.5M+787.2%	$50.2M-0.2%	$50.3M+46.6%	$34.3M+0.2%	$34.3M-17.6%	$41.6M-46.9%	$78.3M
Current Liabilities	$743.4M+46.4%	$507.7M-22.5%	$654.8M+21.8%	$537.7M+118.8%	$245.8M+31.8%	$186.5M-67.0%	$565.3M+540.7%	$88.2M+62.1%	$54.4M+79.0%	$30.4M+18.3%	$25.7M+64.2%	$15.7M+33.9%	$11.7M-25.2%	$15.6M-66.8%	$47.1M
Non-Current Liabilities	$635.0M+2.2%	$621.3M+70.4%	$364.6M+195.9%	$123.2M-72.8%	$452.7M+7.3%	$422.0M+306.6%	$103.8M-75.5%	$424.2M+8.5%	$391.0M+1875.4%	$19.8M-19.6%	$24.6M+31.8%	$18.7M-17.3%	$22.6M-13.1%	$26.0M-16.7%	$31.2M
Total Equity	$3.3B+25.6%	$2.6B+16.0%	$2.2B+30.7%	$1.7B+24.3%	$1.4B+22.0%	$1.1B+76.8%	$636.9M+32.5%	$480.8M+29.2%	$372.2M+18.2%	$314.9M-25.8%	$424.5M+103.4%	$208.7M+73.3%	$120.4M-22.0%	$154.4M+156.9%	$60.1M
Retained Earnings	$447.7M+1433.2%	$29.2M+118.6%	-$157.1M+61.4%	-$406.8M+36.0%	-$635.8M+12.4%	-$725.4M+36.0%	-$1.1B+3.8%	-$1.2B+1.8%	-$1.2B-13.5%	-$1.1B-15.4%	-$915.2M-10.8%	-$826.3M-7.9%	-$765.8M-6.4%	-$719.7M+0.7%	-$724.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.4B+37.8%	$4.9B+33.0%	$4.6B+24.5%	$4.3B+20.7%	$3.9B+17.7%	$3.7B+6.2%	$3.7B+14.4%	$3.5B+24.1%
Current Assets	$1.6B-6.4%	$2.4B+48.7%	$2.5B+46.3%	$2.2B+15.0%	$1.7B+4.7%	$1.6B-9.0%	$1.7B+7.3%	$1.9B+13.7%
Cash & Equivalents	$332.4M+25.9%	$266.5M+37.3%	$713.0M+206.0%	$340.2M-2.5%	$264.0M+89.0%	$194.1M-51.0%	$233.0M-7.2%	$349.1M+18.9%
Short-Term Investments	$57.4M-91.9%	$1.0B+40.1%	$767.4M-9.0%	$774.6M-11.9%	$711.6M-20.9%	$749.4M-8.0%	$843.1M+8.0%	$878.9M+9.7%
Inventory	$104.2M+83.1%	$64.5M+9.1%	$69.0M+20.2%	$69.3M+51.3%	$56.9M+33.9%	$59.1M+58.9%	$57.4M+49.9%	$45.8M+59.0%
Accounts Receivable	$887.0M+48.9%	$768.1M+48.9%	$686.8M+43.4%	$728.0M+51.3%	$595.7M+27.2%	$516.0M+14.5%	$479.1M+9.1%	$481.1M+15.2%
Long-Term Investments	$91.9M-89.5%	$1.3B+63.3%	$1.1B+43.7%	$998.5M+55.1%	$873.8M+37.0%	$815.3M+16.4%	$739.5M+7.6%	$643.9M+41.6%
Goodwill	$500.6M	$6.0M	$6.1M+7.0%	N/A	N/A	N/A	$5.7M-1.7%	$6.1M+10.9%
Total Liabilities	$1.7B+39.3%	$1.5B+30.1%	$1.4B+22.1%	$1.3B+54.7%	$1.2B+50.2%	$1.2B+6.0%	$1.1B+10.8%	$816.1M-3.5%
Current Liabilities	$874.5M+60.1%	$831.7M+59.1%	$743.4M+46.4%	$638.0M+48.5%	$546.3M+37.1%	$522.9M-26.7%	$507.7M-22.5%	$429.7M-37.9%
Non-Current Liabilities	$791.0M+21.8%	$667.1M+6.0%	$635.0M+2.2%	$624.1M+61.5%	$649.2M+63.4%	$629.1M+68.5%	$621.3M+70.4%	$386.4M+150.1%
Total Equity	$3.7B+37.1%	$3.4B+34.4%	$3.3B+25.6%	$3.0B+10.5%	$2.7B+7.4%	$2.5B+6.3%	$2.6B+16.0%	$2.7B+35.8%
Retained Earnings	$724.0M+756.8%	$589.6M+11224.5%	$447.7M+1433.2%	$294.0M+262.5%	$84.5M+273.5%	-$5.3M+95.3%	$29.2M+118.6%	$81.1M+126.6%

Not reported in any period shown, so not listed: Long-Term Debt.

NBIX Cash Flow Statement

NBIX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$898.1M	$782.7M+31.5%	$595.4M+52.7%	$389.9M+14.9%	$339.4M+32.3%	$256.5M+12.3%	$228.5M+55.4%	$147.0M+45.0%	$101.4M+207.5%	-$94.3M+11.2%	-$106.2M-179.4%	-$38.0M+19.4%	-$47.1M-59.2%	-$29.6M+16.1%	-$35.3M-4956.4%	-$698K
Depreciation & Amortization	N/A	$30.1M+11.1%	$27.1M+27.2%	$21.3M+36.5%	$15.6M+43.1%	$10.9M+26.7%	$8.6M+16.2%	$7.4M+83.9%	$4.0M+67.7%	$2.4M+65.2%	$1.5M+44.0%	$1.0M+22.0%	$827K+23.2%	$671K+2.1%	$657K-5.3%	$694K
Stock-Based Compensation	N/A	$217.9M+11.5%	$195.5M+0.6%	$194.3M+12.2%	$173.1M+29.0%	$134.2M+34.2%	$100.0M+32.8%	$75.3M+29.6%	$58.1M+36.6%	$42.5M+49.4%	$28.5M+0.3%	$28.4M+173.5%	$10.4M+52.3%	$6.8M+24.5%	$5.5M+87.8%	$2.9M
Capital Expenditures	$27.7M	$34.0M-11.0%	$38.2M+35.0%	$28.3M+71.5%	$16.5M-29.5%	$23.4M+114.7%	$10.9M-25.9%	$14.7M-40.7%	$24.8M+257.3%	$6.9M+68.9%	$4.1M+112.4%	$1.9M+20.0%	$1.6M+195.8%	$545K-43.9%	$971K+29.5%	$750K
Free Cash Flow	$865.6M	$748.7M+34.4%	$557.2M+54.1%	$361.6M+12.0%	$322.9M+38.5%	$233.1M+7.1%	$217.6M+64.5%	$132.3M+72.7%	$76.6M+175.6%	-$101.3M+8.2%	-$110.3M-176.2%	-$39.9M+18.1%	-$48.8M-61.7%	-$30.2M+16.9%	-$36.3M-2404.5%	-$1.4M
Investing Cash Flow	-$891.2M	-$264.4M-108.5%	-$126.8M+72.9%	-$467.1M-163.7%	-$177.1M-36.0%	-$130.2M-3275.6%	$4.1M+101.9%	-$211.1M+13.1%	-$242.9M+3.3%	-$251.3M-322.4%	$113.0M	N/A	N/A	$5.3M+115.4%	-$34.8M-884.2%	-$3.5M
Financing Cash Flow	$60.2M	-$38.3M+92.1%	-$486.7M-845.3%	$65.3M+127.9%	-$234.3M-955.1%	$27.4M+117.4%	-$157.8M-587.0%	$32.4M+9.8%	$29.5M-94.3%	$516.6M+21517.0%	$2.4M	N/A	N/A	$5.3M-93.7%	$83.7M+29166.4%	$286K
Share Buybacks	$66.0M	$167.7M-44.1%	$300.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$136.4M+33.7%	$145.8M+125.0%	$388.4M+60.2%	$227.5M+44.0%	$102.0M+57.9%	$64.8M-50.3%	$242.5M+96.4%	$158.0M-25.5%
Depreciation & Amortization	$24.8M+239.7%	$7.3M-3.9%	$7.5M+5.6%	$7.7M+18.5%	$7.3M0.0%	$7.6M+22.6%	$7.1M+24.6%	$6.5M+18.2%
Stock-Based Compensation	N/A	$57.2M+8.3%	N/A	N/A	N/A	$52.8M+18.7%	N/A	N/A
Capital Expenditures	$7.8M-37.6%	$9.1M-15.0%	-$2.4M-67.1%	$13.2M+63.0%	$12.5M+7.8%	$10.7M-4.5%	$7.3M+35.2%	$8.1M+6.6%
Free Cash Flow	$128.6M+43.7%	$136.7M+152.7%	$386.0M+64.1%	$214.3M+43.0%	$89.5M+68.9%	$54.1M-54.6%	$235.2M+99.2%	$149.9M-26.7%
Investing Cash Flow	-$135.4M-366.9%	-$506.2M-3664.8%	-$52.9M+22.5%	-$196.7M-896.4%	-$29.0M-2.8%	$14.2M+125.8%	-$68.3M+66.2%	$24.7M+125.4%
Financing Cash Flow	$63.4M+2021.2%	-$86.1M+27.0%	$37.3M+112.9%	$45.6M+72.7%	-$3.3M+98.9%	-$117.9M-268.7%	-$290.0M-919.2%	$26.4M+40.4%
Share Buybacks	$12.0M-32.2%	$54.0M-64.0%	$0-100.0%	$0	$17.7M	$150.0M	$300.0M	$0

Not reported in any period shown, so not listed: Dividends Paid.

NBIX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBIX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	98.2%-0.4pp	98.6%+0.7pp	97.9%-0.5pp	98.4%-0.3pp	98.7%-0.3pp	99.0%	N/A	98.9%-0.3pp	99.2%-0.8pp	100.0%0.0pp	100.0%	N/A	N/A	N/A	N/A
Operating Margin	21.6%-2.6pp	24.2%+10.9pp	13.3%-3.4pp	16.7%+7.7pp	9.0%-6.5pp	15.6%+6.4pp	9.2%+1.0pp	8.2%+89.4pp	-81.3%	-982.5%	-476.5%	N/A	-1701.9%	2.7%-41.1pp	43.8%
Net Margin	16.7%+2.2pp	14.5%+1.3pp	13.2%+2.8pp	10.4%+2.5pp	7.9%-31.0pp	38.9%+34.3pp	4.7%0.0pp	4.7%+92.9pp	-88.2%	-940.6%	-449.8%	N/A	-1579.0%	9.5%-39.1pp	48.5%
Return on Equity	14.7%+1.5pp	13.2%+2.0pp	11.2%+2.1pp	9.0%+2.5pp	6.5%-29.7pp	36.2%+30.4pp	5.8%+1.4pp	4.4%+42.7pp	-38.3%+6.5pp	-44.8%-23.9pp	-20.9%+8.1pp	-29.0%+9.3pp	-38.3%-41.5pp	3.3%-59.3pp	62.5%
Return on Assets	10.3%+1.1pp	9.2%+1.5pp	7.7%+1.2pp	6.5%+2.2pp	4.3%-19.2pp	23.5%+20.7pp	2.8%+0.7pp	2.1%+19.6pp	-17.4%+21.2pp	-38.6%-19.9pp	-18.7%+6.2pp	-24.9%+4.9pp	-29.8%-32.4pp	2.6%-24.6pp	27.2%
Current Ratio	3.390.0x	3.40+0.9x	2.45-0.2x	2.70-1.3x	3.96-1.5x	5.45+4.0x	1.47-6.9x	8.36-1.8x	10.200.0x	10.21-4.7x	14.94+2.3x	12.650.0x	12.69+0.6x	12.10+9.3x	2.81
Debt-to-Equity	0.420.0x	0.440.0x	0.46+0.1x	0.39-0.1x	0.510.0x	0.54-0.5x	1.050.0x	1.07-0.1x	1.20+1.0x	0.160.0x	0.120.0x	0.16-0.1x	0.280.0x	0.27-1.0x	1.30
Asset Turnover	0.620.0x	0.63+0.1x	0.580.0x	0.63+0.1x	0.55-0.1x	0.600.0x	0.60+0.1x	0.45+0.3x	0.20+0.2x	0.040.0x	0.040.0x	0.000.0x	0.02-0.3x	0.27-0.3x	0.56
FCF Margin	26.2%+2.5pp	23.7%+4.5pp	19.2%-2.5pp	21.7%+1.1pp	20.6%-0.3pp	20.8%+4.0pp	16.8%-0.2pp	17.0%+79.6pp	-62.7%	-735.3%	-202.0%	N/A	-1033.0%	-68.2%-66.4pp	-1.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	97.6%-0.8pp	98.3%-0.1pp	97.8%-0.7pp	98.2%-0.5pp	98.4%-0.1pp	98.4%-0.2pp	98.5%+0.2pp	98.7%+1.0pp
Operating Margin	15.8%-5.4pp	23.7%+19.6pp	26.2%+3.6pp	30.1%+0.5pp	21.2%-3.5pp	4.1%-15.2pp	22.6%-6.6pp	29.5%+1.2pp
Net Margin	15.1%-0.6pp	24.3%+22.9pp	19.1%+2.6pp	26.4%+5.5pp	15.6%+4.6pp	1.4%-7.0pp	16.4%-12.2pp	20.9%+4.2pp
Return on Equity	3.9%-0.1pp	5.8%+5.5pp	4.7%+0.7pp	7.0%+2.2pp	4.0%+1.4pp	0.3%-1.5pp	4.0%-2.6pp	4.8%+0.6pp
Return on Assets	2.7%-0.1pp	4.0%+3.8pp	3.3%+0.6pp	4.9%+1.2pp	2.8%+0.8pp	0.2%-1.0pp	2.8%-1.8pp	3.7%+0.8pp
Current Ratio	1.87-1.3x	2.93-0.2x	3.390.0x	3.38-1.0x	3.20-1.0x	3.13+0.6x	3.40+0.9x	4.37+2.0x
Debt-to-Equity	0.450.0x	0.440.0x	0.420.0x	0.42+0.1x	0.44+0.1x	0.450.0x	0.440.0x	0.30-0.1x
Asset Turnover	0.180.0x	0.170.0x	0.170.0x	0.190.0x	0.180.0x	0.160.0x	0.170.0x	0.180.0x
FCF Margin	13.4%+0.4pp	16.8%+7.3pp	47.9%+10.5pp	27.0%+2.9pp	13.0%+4.0pp	9.4%-13.7pp	37.5%+14.5pp	24.1%-16.9pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Neurocrine Biosciences Inc NBIX	FY2025	$2.9B	$478.6M	16.7%	$14.3B	80/100
United Therapeutics Corp UTHR	FY2025	$3.2B	$1.3B	41.9%	$23.2B	88/100
Dr. Reddy's Laboratories Limited RDY	FY2026	$3.6B	$452.0M	12.6%	$10.5B	36/100
Viatris Inc. VTRS	FY2025	$14.3B	-$3.5B	-24.6%	$20.4B	28/100
Teva Pharmaceutical Industries Limited TEVA	FY2025	$17.3B	$1.4B	8.2%	$46.2B	34/100

Where Neurocrine Biosciences Inc Ranks

Frequently Asked Questions

What is Neurocrine Biosciences Inc's annual revenue?

Neurocrine Biosciences Inc (NBIX) reported $2.9B in total revenue for fiscal year 2025. This represents a 21.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Neurocrine Biosciences Inc's revenue growing?

Neurocrine Biosciences Inc (NBIX) revenue grew by 21.4% year-over-year, from $2.4B to $2.9B in fiscal year 2025.

Is Neurocrine Biosciences Inc profitable?

Yes, Neurocrine Biosciences Inc (NBIX) reported a net income of $478.6M in fiscal year 2025, with a net profit margin of 16.7%.

What is Neurocrine Biosciences Inc's EBITDA?

Neurocrine Biosciences Inc (NBIX) had EBITDA of $649.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Neurocrine Biosciences Inc's gross margin?

Neurocrine Biosciences Inc (NBIX) had a gross margin of 98.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Neurocrine Biosciences Inc's operating margin?

Neurocrine Biosciences Inc (NBIX) had an operating margin of 21.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Neurocrine Biosciences Inc's net profit margin?

Neurocrine Biosciences Inc (NBIX) had a net profit margin of 16.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Neurocrine Biosciences Inc's return on equity (ROE)?

Neurocrine Biosciences Inc (NBIX) has a return on equity of 14.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Neurocrine Biosciences Inc's free cash flow?

Neurocrine Biosciences Inc (NBIX) generated $748.7M in free cash flow during fiscal year 2025. This represents a 34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Neurocrine Biosciences Inc's operating cash flow?

Neurocrine Biosciences Inc (NBIX) generated $782.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Neurocrine Biosciences Inc's total assets?

Neurocrine Biosciences Inc (NBIX) had $4.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Neurocrine Biosciences Inc's capital expenditures?

Neurocrine Biosciences Inc (NBIX) invested $34.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Neurocrine Biosciences Inc spend on research and development?

Neurocrine Biosciences Inc (NBIX) invested $1.0B in research and development during fiscal year 2025.

Does Neurocrine Biosciences Inc buy back shares?

Yes, Neurocrine Biosciences Inc (NBIX) spent $167.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Neurocrine Biosciences Inc have outstanding?

Neurocrine Biosciences Inc (NBIX) had 100M shares outstanding as of fiscal year 2025.

What is Neurocrine Biosciences Inc's current ratio?

Neurocrine Biosciences Inc (NBIX) had a current ratio of 3.39 as of fiscal year 2025, which is generally considered healthy.

What is Neurocrine Biosciences Inc's debt-to-equity ratio?

Neurocrine Biosciences Inc (NBIX) had a debt-to-equity ratio of 0.42 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Neurocrine Biosciences Inc's return on assets (ROA)?

Neurocrine Biosciences Inc (NBIX) had a return on assets of 10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Neurocrine Biosciences Inc's P/E ratio?

Neurocrine Biosciences Inc (NBIX) trades at 20.3x earnings, its market capitalization divided by net income of $705.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $14.3B as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Neurocrine Biosciences Inc's price-to-sales ratio?

Neurocrine Biosciences Inc (NBIX) trades at 4.2x sales, its market capitalization divided by revenue of $3.4B revenue, trailing 12 months to June 30, 2026. The market capitalization is $14.3B as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Neurocrine Biosciences Inc's Altman Z-Score?

Neurocrine Biosciences Inc (NBIX) has an Altman Z-Score of 7.88, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Neurocrine Biosciences Inc's Piotroski F-Score?

Neurocrine Biosciences Inc (NBIX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Neurocrine Biosciences Inc's earnings high quality?

Neurocrine Biosciences Inc (NBIX) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Neurocrine Biosciences Inc?

Neurocrine Biosciences Inc (NBIX) scores 80 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.